Condition: End-stage Liver Disease (ESLD) · Cirrhosis, Liver · Cirrhosis, Decompensated · Sponsor: Resolution Therapeutics Limited
The purpose of this study is to assess the safety and efficacy of RTX001 in patients with end-stage liver disease. This study is the first time RTX001, a macrophage cell therapy engineered to have an anti-inflammatory and anti-fibrotic effect, will be given to humans.
This description comes directly from the study's public registry record.
Resolution Therapeutics Clinical Enquiries · +442037811105 · clinical.enquiries@resolution-tx.com
Always discuss trial participation with your own doctor first.
| Hospital Universitari Vall d'Hebron | Barcelona, Spain | Recruiting |
| Hospital Universitario Reina Sofía | Córdoba, Spain | Recruiting |
| Hospital General Universitario Gregorio Marañon | Madrid, Spain | Recruiting |
| Hospital Universitario Ramón y Cajal | Madrid, Spain | Recruiting |
| Hospital Universitario La Paz | Madrid, Spain | Recruiting |
| Hospital Universitario Virgen del Rocío | Seville, Spain | Recruiting |
| Bristol Royal Infirmary | Bristol, United Kingdom | Recruiting |
| Royal Infirmary of Edinburgh | Edinburgh, United Kingdom | Recruiting |
| Glasgow Royal Infirmary | Glasgow, United Kingdom | Recruiting |
| Royal Liverpool University Hospital | Liverpool, United Kingdom | Recruiting |
| King's College Hospital | London, United Kingdom | Recruiting |
| St George's Hospital | London, United Kingdom | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06823713